The Omics Brief | Next-Gen FFPE Proteomics: Turning yesterday’s tissue into tomorrow’s breakthroughs

Discovering novel functional markers that capture tumor biology, TME interactions, and drug response/resistance in archived tissue.

Mass Spectrometry-Based FFPE Proteomics as a Transformational Platform for Modern Oncology R&D

Going beyond IHC to, for the first time, directly quantify the functional protein landscape of tumors in FFPE samples.

Inside Sapient’s Multi-Omics Revolution: A Deep Dive with Founder Mo Jain

PharmaShots delves into Sapient’s mission to transform multi-omics research through innovation & world-class partnerships.

FFPE Multi-Omics for Precision Oncology Platforms

Extending molecular insights beyond DNA and RNA to realize new value in existing FFPE tissue biobanks.

The Bio Report: “Rewriting Drug Discovery with an AI-Multi-Omics Approach”

A look at how AI-driven, multi-omics platforms are advancing the discovery and development of precision medicines.

FFPE Multi-Omics for Clinical Oncology

Unlocking functional biology, new biomarker insights, and responder profiles from archived trial samples.

The Omics Brief | Proteomics at the Edge: Mapping the Cell Surface for Target Discovery

Using TAA profiling to identify differentially expressed, disease-modifying, tractable targets on the cell surface.

FFPE Multi-Omics for Translational Oncology

Delivering quantitative, reproducible protein measures for rapid proof-of-mechanism & target engagement insights.

Systematic Inflammatory Profiling Reveals Immune Modulation in Response to Weight Loss Intervention

Using multi-omics to characterize changes in inflammatory markers observed following GLP-1 therapy.

FFPE Multi-Omics for Discovery Oncology

Transforming archival tissue into a discovery-ready resource to move from target discovery to functional validation, in weeks.